An interventional study of OneTouch Verio® and OneTouch Verio® Flex in Diabetes Mellitus, sponsored by LifeScan. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-08-15.
Sponsored by LifeScan (formerly part of Johnson & Johnson) · Not applicable, Interventional, and Other
To investigate whether novel insight features in new BGMs can improve glycemic control.
11,089 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's planned enrollment of 267 is above the median of 80 across 8,491 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →LifeScan is the lead sponsor of 15 studies on the registry; none are open to participants now.
First submitted before LifeScan left Johnson & Johnson.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria Summary:
Subject continue to use their own Blood Glucose Monitoring System ( BGMS) for 12 weeks.
Device: Subject's Own Blood Glucose Meter
Subjects use LifeScan provided BGMS (OneTouch Verio®) for 12 weeks
Device: OneTouch Verio®
Subjects use LifeScan provided BGMS (OneTouch Verio® Flex ) for 12 weeks.
Device: OneTouch Verio® Flex
Colour Enhanced Blood Glucose Meter.
Colour Enhanced Blood Glucose Meter.
Subject's Own Blood Glucose Meter
A1c change from baseline after 12 weeks
A1c change from baseline after 12 weeks in subjects using BGMs with color range indicator and/or pattern messaging tools (i.e., OneTouch Verio® Flex and OneTouch Verio® combined) compared to subjects with either T1 or T2DM using their current BGM, i.e., without color range indicator and/or pattern messaging tools.
Time frame: 12 weeks
Plan to share: No
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.